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Abstract
Background: Alpha 1 antitrypsin (A1AT) deficiency (A1ATD) is potentially associated with a high degree of liver
and/or lung disease. Apart from the most frequent deficiency alleles, Pi S and Pi Z, some A1AT alleles of clinical
significance may be easily misdiagnosed. This is typically the case of the Pi Mmalton variant which shares the same
‘gain-of-function’ liver toxicity than Pi Z and the same ‘loss of function’ lung disease as well.
Methods: The biological diagnosis of A1ATD typically relies on a low serum concentration associated with an
abnormal isoelectric focusing (IEF) pattern of migration. However, Sanger direct DNA sequencing may be required
for deficiency alleles without biochemical expression (Null alleles) or for A1AT variants whose IEF profiles resemble
the wild-type and sub-types M allele but with a low concentration.
Results: We report four cases of A1ATD involving the deficient Pi Mmalton allele with very different clinical
expressions: (i) one Mmalton/Mmalton with liver fibrosis and cirrhosis, (ii) two Mmalton/Z with chronic pulmonary
obstructive disease in one case and (iii) one M/Mmalton without liver or lung disease. In both cases, the correct
diagnosis has necessitated a genetic analysis.
Conclusions: Our study provides another example of Pi Mmalton homozygosity associated with a severe liver
disease that emphasizes the necessity of a not delayed diagnosis. The great clinical heterogeneity of the other
genotypes (which is in agreement with the literature data) questions about the role of environmental and other
modifier genes in the pathogenicity of A1ATD.
Background
Alpha 1 antitrypsin (A1AT) deficiency (A1ATD) is a com-
mon autosomal co-dominant genetic disorder caused by
mutations on the SERPINA1 gene (chromosome 14) that
may be clinically characterized by lung (emphysema,
chronic obstructive pulmonary disease-COPD) and/or
liver (cirrhosis) disease. These two different clinical ex-
pressions reflect the two pathophysiological pathways of
A1ATD which are respectively designated as the ‘loss-of-
function’ and ‘gain-of-function’ mechanisms [1]. In the
first one, low A1AT plasma concentrations are respon-
sible for the pulmonary parenchyma destruction since
the local degradation of neutrophil elastase is strongly
reduced. It is caused by A1AT deficient variants but
also by “Null” SERPINA1 alleles which have no proteic
expression at all [2, 3]. In the second one, the liver
disease is mediated by the aggregation of misfolded
A1AT molecules into ordered polymers that become
sequestered in characteristic inclusions within the
endoplasmic reticulum (ER) of hepatocytes, thus lead-
ing to their apoptosis.
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Several regions within the molecule of A1AT control
the conformational changes which occur during the
process of protease inhibition [4]. One of these, called
the breach, is located at the top of β-sheet A where the
reactive center loop inserts after cleavage by the protein-
ase. The importance of this region is reflected the pres-
ence of highly conserved residues and by the fact that
the most frequent point mutation associated with severe
A1ATD (Glu342Lys) is precisely located in the breach.
The resulting Z-proteins undergo intra-hepatocyte
polymerization causing liver damage and low circulating
A1AT concentration promoting development of COPD.
Another region located in the middle of the serpin,
called the shutter, is also characterized by the presence
of conserved residues. It controls the opening of the A-
sheet and mutations in that region result in dysfunc-
tional A1AT variants that are associated with a severe
A1ATD and hepatic inclusions due to the formation of
loop-sheet polymers: Pi Siiyama (Ser53Phe) and Pi
Mmalton (Phen52del) [5, 6] (also known as Mnichinan if
associated with Gly148Arg). Two other deficient variants
in the shutter region, namely Pi S (Glu264Val) [7] and Pi
I (Arg39Cys) [8], also induce polymerization but their
rates of polymers formation are much slower than for Pi
Z, Pi Siiyama and Pi Mmalton, thus leading to a milder
plasma deficiency without liver disease.
A1ATD is present in all racial subgroups worldwide
but with striking differences in the calculated prevalence
of the PiZ phenotype. For instance, this prevalence is
about 1 out of 7500 individuals in Southern Europe
(Spain, Portugal, France and Italy) [9], 1 out of 2700 in
Northern Europe and 1 out of 18,000 in central Europe
[10]. As stated by de Serres, A1ATD is not a rare condi-
tion but a condition that is rarely diagnosed [11]. As a
matter of fact, it is estimated that in Europe and in the
USA, less than 10 % of the expected individuals with Pi
Z phenotype are identified [12]. Because the condition is
thought to be rare, physicians are not familiar with the
symptoms which are often categorized as common
COPD without addressing the possibility of A1ATD. An-
other reason might be the costs of the tests which are
expensive and not always easily available. Luckily, since
a few years, as there is a growing interest in AATD, rarer
variants are more often identified [1, 13] and, among
them, some are polymerogenic and can be associated
with a mildly or severely decreased concentration of
A1AT that may lead to emphysema and/or liver disease:
Pi Queen’s (Lys154Asn), Pi Pbrescia (Gly225Arg), Pi
Mpisa (lys259Ile), Pi King’s (His334Asp), Pi Etaurisano
(Lys368Glu), Pi Yorzinuovi (Pro391His), Pi Wurzburg
(Pro369Ser) and Pi Mheerlen (Pro369Leu).
The currently used algorithm for the laboratory diag-
nosis of A1ATD combines quantification, phenotyping
and genotyping [14]. Quantification is mostly realized
using immunological procedures such as immunoturbi-
dimetry or immunonephelometry whereas phenotyping
is usually assessed with isoelectric focusing (IEF) in a
narrow pH gradient on polyacrylamide or agarose gels.
While the American Thoracic Society/European Respira-
tory Society stated it as the gold standard for the A1AT
‘genetic testing’ in their 2003 report [15], IEF presents
some drawbacks with Q0 alleles and rare deficient vari-
ants that imply to resort to genotyping. Unfortunately,
the most common genetic techniques which rely on a
specific search for the Pi Z and Pi S alleles by restriction
length fragment polymorphism (RFLP) [16] or fluores-
cence resonance energy transfer (FRET) [17] do not also
identify Q0 alleles and rare deficient variants. Thus, they
should always be associated with the quantification of
the protein, otherwise a non S/non Z patient might be
considered as having a non pathological phenotype while
he might be Pi Mmalton/Null for instance. So, when a
low concentration of A1AT cannot be attributed to a Pi
ZZ genotype, the direct Sanger sequencing of the entire
SERPINA1 gene and/or specific PCR based methods for
some rare or Null variants must be performed until an
explanation can be found [18]. A few Q0 alleles caused
by the deletion of one or more of the SERPINA1 gene
coding exons have also been described [19].
Methods
In the present paper, we describe four cases in which the
Pi Mmalton allele was first biologically and/or clinically
suspected before being confirmed by Sanger DNA se-
quencing. Interestingly, 3 different genotypic situations
are explored: Mmalton/Mmalton (patient 1), Mmalton/Z
(patients 2 and 3) and M/Mmalton (patient 4). All four
probands signed a written agreement for genetic analysis
according to the Helsinki declaration.
Case 1: Mmalton/Mmalton
A 80-year-old woman of Algerian origin was admitted
to hospital for the treatment of an acute and painful
fracture of the third lumbar vertebra. A computed tom-
ography scan (CTS) was performed for this fracture
and revealed a dysmorphic and enlarged liver with signs
of portal hypertension (splenomegaly, collateral veins).
Her past medical history was significant for obesity,
vertebral osteoporosis, monoclonal gammapathy of un-
determined significance (IgG kappa) and some bron-
chitis episodes in the past 2 years. She had neither
history of liver disease nor alcohol, tobacco or illicit
drug abuse. Her medical examination revealed the ab-
sence of ascites, peripheral edema, jaundice and aster-
ixis. Laboratory tests showed abnormal liver function
tests: alkaline phosphatase, 382 UI/L (reference inter-
val, 45–117 UI/L); gamma-glutamyl-transpeptidase, 299
UI/L (reference interval, 5–55 UI/L) aspartate
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aminotransferase, 56 UI/L (reference interval, 15–37
UI/L); alanine aminotransferase, 25 UI/L (reference
interval, 12–78 UI/L); total serum bilirubin, 0.94 mg/dL
(reference interval, 0.176–1.0 mg/dL). Serum albumin
was decreased, 29 g/L (reference interval, 35–50 g/L).
Blood platelets count was low, 143 × 109/L (normal
range, 150–400 × 109/L). INR was 1.2 and serum creati-
nin was 47 μmol/L. Liver stiffness measurement by
transient elastography (Fibroscan®) was pathologic with
an increased value of 21.3 kPa in favor of underlying
cirrhosis (normal range <7–8 kPa). A gastroscopy re-
vealed grade 2 esophageal varices with red spots which
were treated by band ligation. The serological tests for
viral hepatitis and autoimmune hepatitis were negative.
Serum cholesterol, triglycerides, ceruloplasmin and fer-
ritin levels were normal.
Protein serum electrophoresis (Capillarys®, Sebia) re-
vealed a marked decrease of the α1-globulin fraction
strongly suggesting an A1AT deficiency. The low serum
A1AT level determined by immuno-nephelometry
(0.34 g/L, reference interval: 1.0–1.8 g/L) and the iso-
electric pattern with faint bands slightly more cathodal
than M2 bands were very suggestive of a Pi Mmalton al-
lele at the homozygous state. To confirm this diagnosis,
we performed the Sanger DNA sequencing of the entire
SERPINA1 gene with the ABI Prism 3130XL (Applied)
as previously described [20]. Sequence analysis (Fig. 1) re-
vealed the presence, at the homozygous state, of a deletion
of the three nucleotides TTC in codon 52 (exon 2) corre-
sponding to the Mmalton allele (HGVS nomenclature:
SERPINA1:c.154_156del; p. Phe52del). This deletion was
on a M2 background since it was associated with the
homozygous c.374G > A and c.1200A > C single nucleo-
tide polymorphisms, thus defining the Pi Mmalton allele
(the Phe52deletion on a M1 background has been called
Pi Palermo). A percutaneous liver biopsy revealed micro-
nodular cirrhosis, without steatosis but with periodic acid-
Schiff (PAS)-positive acidophilic, diastase-resistant bodies
in the cytoplasm of the hepatocytes. Immunohistochemi-
cal staining using a monoclonal antibody to A1AT was
positive (Fig. 2). According to Child-Pugh classification
and MELD score, the cirrhosis was Child-Pugh B7, MELD
9. With regards to the lung, a thoracic CT scan revealed
few lesions of bronchiectasis but without lesions of em-
physema and the pulmonary function tests were within
the normal range.
Cases 2 & 3: Mmalton/Z
A 41-year-old man of French Caucasian origin was hos-
pitalized for severe dyspnea. According to his medical
records, he suffered from COPD, chronic emphysema
and had presented with many bronchitis episodes in his
youth, when he used to be a frequent smoker. A 37-
year-old woman of French Caucasian origin was seen in
medical consultation for asthma and bronchiectasis. Her
medical history revealed allergic asthma equilibrated by
Symbicort® but no sign of COPD.
In both cases, the biochemical A1AT analysis re-
vealed a very low serum level (0.33 and 0.22 g/L, re-
spectively) and a Pi Z phenotype at IEF but a genetic
confirmation performed with a RFLP method specific
for the Pi Z and Pi S alleles identified the Pi Z allele at
the heterozygous state only. This discrepancy could be
solved by Sanger DNA sequencing which revealed a Pi
Fig. 1 Part of DNA sequencing of the SERPINA1 gene, showing the deletion of three nucleotides in exon 2, codon 52 (TTC > 0) at the homozygous
state (a Phe amino acid residue is deleted). HGVS nomenclature: SERPINA1:c.154_156del; p. Phe52del
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Mmalton/Pi Z compound heterozygosity. Hepatic func-
tion tests were then performed for both patients but they
appeared normal.
Case 4: M/Mmalton
A 57-year-old woman of Moroccan origin suffering from
an end-stage kidney disease was admitted for pre-kidney
transplant investigations. Her medical story revealed
diabetes with various peripheral vascular complications
but neither pulmonary nor hepatic dysfunction. Serum
electrophoresis revealed a double α1-globulin peak, sug-
gesting the presence of a Pi A1AT protein variant in the
heterozygous state. The A1AT IEF phenotype was noted
Pi M1/Pi M2 but because of an abnormally low serum
concentration (69 mg/dL), DNA sequencing was per-
formed and revealed a Pi M1/Pi Mmalton genotype.
Results and discussion
The Pi Mmalton variant was first discovered by Cox in
1976 [21]. Maybe because of a similar genetic back-
ground with the normal Pi M2 allele, it is characterized
by a slightly more cathodal mobility than M2 on IEF
gels. At the heterozygous state, it thus may be con-
founded with an M protein [22] but such a confusion
can easily be prevented by A1AT quantification since a
Pi MM genotype is much of the time not compatible
with an A1AT serum value below 1 g/L which is ob-
served in that case. The situation is more complex and
the Pi Mmalton variant can easily be missed when it is
associated with a Pi Z protein [23] or with any other rare
A1AT allele [24]. At the homozygous state, the Pi Mmal-
ton protein is clearly visible on the IEF gel (Fig. 3) and
this situation is phenotypically undistinguishable from a
Null/Pi Mmalton compound heterozygosity. A Sanger
direct sequencing is thus required for the differential
diagnosis which is important because of the liver domin-
ant negative effect of the Pi Mmalton variant. The exact
pathogenesis is incompletely known but it seems that
apoptosis is more pronounced in hepatocytes with
greater levels of insoluble polymerized/aggregated forms
of A1AT that accumulate in the ER, the soluble forms
being more specifically degraded by the proteasome [25].
The first cases of Pi Mmalton homozygosity were re-
ported in 1987 by Reidl (association of emphysema,
cirrhosis, and hepatocellular carcinoma in a 63-year old
Fig. 2 Liver tissue was obtained by percutaneous liver biopsy of the
proband. a Hematein Phloxin Safran (HPS) coloration showing collagen
fibrosis around hepatocytes with numerous round eosinophilic
cytoplasmic inclusions; (b) PAS staining with diastase digestion
showing abundant hyaline globules containing A1AT accumulated
within periportal hepatocytes; (c) Immunohistochemical staining using
a monoclonal antibody to A1AT
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white man) [26] and in 1989 by Curiel (47-year-old male
patient with a 20-pack-year smoking history suffering
from emphysema and hepatic inflammation) [27]. Up to
these case reports, the Pi Mmalton protein was thought
to be associated with emphysema only. In case 1, be-
cause of the paucity of the known proband’s medical
records, it was not possible to determine when the hep-
atic disease appeared but the fibrosis had certainly begun
many years ago since a quite advanced cirrhosis was
present at the time of diagnosis. The fact that no pul-
monary disease was observed is probably explained by
the non-smoker profile of the proband.
Since then, with the growing interest in A1ATD, the
improvement in the genetic techniques and the know-
ledge that there were deficient variants others than S
and Z, some studies were devoted to the prevalence
and clinical phenotypes of subjects carrying rare defi-
cient variants. It appeared among other things that the
Pi Mmalton variant was not as rare as previously
thought: indeed it seems that it is the most frequent de-
ficient variant in Sardinia [28] and Tunisia [29] and the
third one (after Pi S and PiZ) in Spain [30]. It is note-
worthy that 2 of our 4 reported patients were issued
from the Maghreb countries. Since there is a large ma-
ghrebian community in France, it would be important
to set a strategy of A1ATD diagnosis allowing not to
miss the possibility of a Pi Mmalton allele. It becomes
also necessary to document the clinical phenotypes of
homozygous and heterozygous patients. Ferrarotti [28]
reported that liver disease was detected in 13 % of sub-
jects that were either homozygous or heterozygous for
the PiMmalton variant compared to 11 % in Pi ZZ pa-
tients. The Mmalton/Z and M/Mmalton have also been
frequently observed in the literature and they were
associated with very different clinical states. Cox made
the first description of the PiMmalton variant in a fam-
ily exhibiting Pi MmaltonZ and Pi MmaltonM pheno-
types without any liver or lung involvement but all
members were below 30 years of age [21]. On the other
hand, Canva et al. described a case of a Mmalton/M
59-year-old woman with end-stage liver disease, despite
no history of hepatitis, alcohol abuse or childhood
liver disease [31]. Between these two extremities, most
of the described M/Mmalton patients had normal
pulmonary and liver functions while the Mmalton/Z
genotype was often, but not always, associated with a
high risk of developing emphysema, particularly in
smokers [26, 32, 33].
The case-reports presented in the present study are
in accordance with that: patient 2, who was a smoker,
suffered from COPD while patient 3, a non-smoker,
had no major pulmonary sign. For both patients, their
young age at the time of observation has probably pre-
vented them from any hepatic disorder. Obviously,
exposure of environmental factors is also of major im-
portance in the apparition of the lung and liver diseases
for Mmalton/Z patients. It is very well-known and evident
in the former (tobacco and emphysema) but it is true as
well in the latter since any drug or toxic (ethanol), that
negatively regulates autophagy, worsens liver apoptosis.
Conversely, recent studies have shown that carbamazepin,
a drug that enhances autophagy, decreases the hepatic fi-
brosis in a mouse model of A1ATD [34]. Thus, clear
genotype-phenotype relationships deficiency in A1ATD
would necessitate large cohorts to withdraw the environ-
mental bias.
Fig. 3 Isoelectric focusing gel showing a pure Pi Mmalton profile among the main other classical A1AT Pi profiles: 1:M1M2; 2:M1; 3:M1M4;
4:M1M3; 5:M1V; 6:M1X; 7: M1S; 8: Mmalton; 9:M1Z; 10:M2Z; 11:Z; 12:M1Z et 13:M3Z. We can particularly notice the very weak expression of the
bands in the Mmalton lane compared to others lanes. This ‘pure’ Mmalton profile can correspond to a Mmalton homozygosity or a Mmalton/Null
compound heterozygosity
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Conclusions
As stated above, the Pi Mmalton variant is very import-
ant to diagnose and should never be missed once an
A1AT examination has been prescribed by a physician.
To do so, medical biologists implied in the diagnostics
of AATD should at least be aware of the pattern of mi-
gration of the PiMmalton protein and be very cautious
in front of any discrepancy with the A1AT serum level.
If a genetic analysis has to be done, Sanger direct se-
quencing is highly recommended to ensure a 100 %
sensibility whatever the SERPINA1 allele.
Our study confirms the great clinical heterogeneity of
the Mmalton/Z genotypes but, obviously, the exposure
of environmental factors complexifies much the inter-
pretation for such small series of patients. Very inter-
estingly, a rapid and reliable genetic method for the
detection of the Pi Mmalton allele on whole blood,
serum and dried blood spot has just been published
[35]. Using it in a large-scale screening would allow to
obtain information about the real prevalence of the Pi
Mmalton allele and to constitute large series of patients
for a proper phenotype-genotype relationship.
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